Risk Factor | Univariate analysis | Multivariable analysisa | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Brain PFS | OS | Brain PFS | OS | |||||||||
HR | 95 % CI | P | HR | 95 % CI | P | HR | 95 % CI | P | HR | 95 % CI | P | |
Prior capecitabine vs. no prior capecitabine | 1.20 | 0.68-2.11 | 0.5377 | 1.22 | 0.67-2.22 | 0.5195 | ||||||
Hormone receptor positive vs. hormone receptor negative | 0.56 | 0.31 -1.00 | 0.0507 | 0.62 | 0.34-1.13 | 0.1190 | 0.38 | 0.20-0.72 | 0.0031 | |||
Best systemic response SD < 6 m, PD vs. CR, PR, SD ≥ 6 m | 2.47 | 1.39-4.40 | 0.0022 | 3.55 | 1.89-6.67 | <0.0001 | ||||||
Median trastuzumab duration, wks ≥35.4 vs. <35.4 | 0.85 | 0.48-1.50 | 0.5672 | 0.45 | 0.24-0.85 | 0.0140 | 0.50 | 0.25-0.99 | 0.0476 | |||
Age at ≥50 vs. <50 | 0.67 | 0.36-1.23 | 0.1925 | 1.13 | 0.61-2.13 | 0.6958 | ||||||
No. of metastasis ≥3 vs. <3 | 0.81 | 0.44-1.48 | 0.4918 | 1.10 | 0.57-2.13 | 0.7733 | ||||||
No. of prior chemotherapy regimens >3 vs. ≤ 3 | 0.88 | 0.48-1.61 | 0.6835 | 1.48 | 0.79-2.76 | 0.2169 | ||||||
Pattern of metastasis Visceral only vs other | 1.51 | 0.80-2.85 | 0.1994 | 1.16 | 0.58-2.31 | 0.6778 | ||||||
Median TTbrainP, wks ≥30.7 vs. <30.7 | 0.44 | 0.24-0.82 | 0.0095 | 0.58 | 0.29-1.16 | 0.1223 | ||||||
Median interval from brain metastasis diagnosis to study enrollment, wks ≥8.1 vs. <8.1 | 1.42 | 0.80-2.53 | 0.2365 | 1.49 | 0.81-2.74 | 0.2032 | ||||||
Brain response* SD < 6 m, PD vs. CR, PR, any response, SD ≥ 6 m | 7.44 | 3.42-16.18 | <0.0001 | 1.79 | 0.85-3.77 | 0.1263 | ||||||
Brain response & systemic response Else vs . Both of CR, PR, SD ≥ 6 m | 2.82 | 1.57-5.09 | 0.0006 | 3.16 | 1.68-5.96 | 0.0004 | 3.65 | 1.95-6.85 | <0.0001 | 2.18 | 1.07-4.42 | 0.0311 |